Nasdaq:CTKB
Cytek Biosciences, Inc.
CTKB develops and commercializes advanced flow cytometry and imaging systems that enable breakthrough discoveries in immunology and oncology research.
Key Metrics
Investment Thesis
Bull Case
CTKB offers a compelling turnaround story for investors willing to tolerate short-term volatility in exchange for long-term monopoly-like returns on its proprietary spectral cytometry platform. The company's technology is essential for modern immunology research, creating high barriers to entry that could eventually drive significant pricing power and margin expansion once the current burn rate stabilizes. Potential acquisition interest from larger biotech or medical device conglomerates looking to bolster their single-cell capabilities remains a realistic catalyst given the firm's specialized asset base.
Bear Case
The investment case is severely undermined by an unsustainable loss of $66.5M and a massive cash burn that has depleted liquidity reserves, forcing reliance on capital markets or asset sales for survival. Revenue growth has stalled near $200M while expenses continue to escalate, indicating an inability to scale profitability effectively in the current market environment. Without a clear path to positive free cash flow or a strategic acquisition within the next 12-18 months, the company faces a high risk of dilution through equity issuances or bankruptcy.
About Cytek Biosciences, Inc.
Cytek Biosciences Inc (CTKB) is a premier provider of flow cytometry and imaging technologies serving life sciences research and clinical diagnostics markets. The company specializes in high-performance instruments for immune monitoring, drug development, and precision medicine applications. Key products include the Cytek Aurora, a next-generation instrument designed to enhance single-cell analysis capabilities.
Analysis
Management Discussion
Despite recording top-line growth from $164M in 2022 to $201.5M in 2025, profitability has deteriorated sharply with net income plunging from a modest $2.5M gain to a severe $66.5M loss over the same period. The cash flow statement reveals significant outflows from financing activities of $13.4M and investing activities, partially offset by large proceeds from marketable securities but resulting in a net cash decrease of $7.9M. Operating expenses surged alongside revenue growth, particularly with general and administrative costs reaching $58.9M and marketing expenses at $49.4M, yet these were insufficient to cover the cost of revenue which stood at $97.0M.
Industry Overview
The global life sciences instrumentation industry is experiencing rapid innovation driven by the shift towards single-cell and spatial analysis technologies. While market demand for advanced flow cytometry remains robust, competition is intensifying from established giants like Thermo Fisher and emerging startups disrupting traditional business models. Regulatory scrutiny and reimbursement dynamics in clinical diagnostics also add complexity to revenue recognition and long-term growth projections.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $164.0M | $193.0M | $200.5M | $201.5M |
| Cost of Revenue | $63.1M | $83.6M | $89.3M | $97.0M |
| Gross Profit | $101.0M | $109.4M | $111.1M | $104.5M |
| Operating Expenses | $102.8M | $137.3M | $131.6M | $144.8M |
| Operating Income | $-1.8M | $-27.8M | $-20.5M | $-40.4M |
| R&D | $34.9M | $44.2M | $39.4M | $36.5M |
| G&A | $34.7M | $44.0M | $43.1M | $58.9M |
| Marketing | $33.2M | $49.1M | $49.1M | $49.4M |
| Stock-Based Comp | $16.6M | $22.0M | $26.8M | $24.6M |
| D&A | $2.5M | $6.0M | $7.2M | $7.6M |
| Depreciation | $1.7M | $2.8M | $3.5M | $3.9M |
| Amortization | $835.0K | $3.3M | $3.7M | $3.7M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $3.1M | $12.1M | $14.8M | $10.5M |
| Interest Expense | $2.6M | $2.1M | — | — |
| Interest Income | $4.6M | $6.4M | $5.1M | $2.2M |
| Pre-Tax Income | $1.3M | $-15.7M | $-5.7M | $-29.8M |
| Income Tax | $-1.2M | $-3.6M | $320.0K | $36.7M |
| Continuing Ops | $2.5M | $-12.1M | $-6.0M | $-66.5M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $2.5M | $-12.1M | $-6.0M | $-66.5M |
| Minority Interest | $92.0K | $0 | $0 | $0 |
| Net to Common | $2.4M | $-12.1M | $-6.0M | $-66.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $454.0M | $392.1M | $396.4M | $392.0M |
| Cash & Equivalents | $296.6M | $167.3M | $98.7M | $90.9M |
| Accounts Receivable | $48.9M | $55.9M | $60.6M | $62.5M |
| Inventory | $48.2M | $60.9M | $43.9M | $48.4M |
| Prepaid Expenses | $13.0M | $12.5M | $14.1M | $19.5M |
| Other Current Assets | $47.4M | $95.4M | $179.2M | $170.7M |
| Long-Term Assets | $65.5M | $102.4M | $103.1M | $69.5M |
| PP&E (Net) | $13.7M | $18.4M | $18.0M | $18.0M |
| Intangibles | $4.3M | $23.1M | $20.1M | $16.8M |
| Goodwill | $10.1M | $16.2M | $16.7M | $16.7M |
| Operating Leases | $13.9M | $10.9M | $10.2M | $11.3M |
| Other LT Assets | $21.8M | $32.3M | $36.5M | $5.1M |
| Total Assets | $519.5M | $494.5M | $499.5M | $461.5M |
| Current Liabilities | $49.0M | $56.2M | $67.7M | $77.8M |
| Current Leases | $2.9M | $2.4M | $3.8M | $2.9M |
| Deferred Revenue | $26.1M | $37.8M | $25.5M | $28.5M |
| Taxes Payable | $246.0K | $1.3M | $1.5M | $3.1M |
| Other Current Liab | $-1.4M | $-5.4M | $15.5M | $19.9M |
| Long-Term Liabilities | $44.9M | $45.2M | $36.1M | $42.0M |
| LT Operating Leases | $12.3M | $9.5M | $7.6M | $14.0M |
| Other LT Liab | $32.6M | $35.7M | $12.4M | $9.6M |
| Total Liabilities | $93.9M | $101.4M | $103.8M | $119.8M |
| Shareholders' Equity | $425.5M | $393.1M | $395.7M | $341.7M |
| Paid-In Capital | $442.9M | $423.4M | $430.8M | $441.1M |
| Retained Earnings | $-17.0M | $-29.2M | $-35.2M | $-101.7M |
| AOCI | $-697.0K | $-1.3M | $16.0K | $2.2M |
| Total L&E | $519.5M | $494.5M | $499.5M | $461.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $2.5M | $-12.1M | $-6.0M | $-66.5M |
| Non-Cash Adjustments | $-90.2M | $-48.5M | $-18.2M | $-16.0M |
| Working Capital Changes | $75.5M | $65.9M | $49.6M | $77.9M |
| Cash from Operations | $-12.2M | $5.3M | $25.4M | $-4.7M |
| Capital Expenditures | $9.7M | $4.6M | $3.5M | $4.1M |
| Cash from Investing | $-55.9M | $-93.9M | $-83.0M | $10.1M |
| Share Buybacks | — | $44.2M | $21.6M | $15.1M |
| Cash from Financing | $5.5M | $-41.8M | $-15.8M | $-13.4M |
| FX Effect | $-2.5M | $-1.4M | $4.5M | $109.0K |
| Net Change in Cash | $-65.1M | $-131.9M | $-68.9M | $-7.9M |
| Beginning Cash | $364.6M | $299.5M | $167.6M | $98.7M |
| Ending Cash | $299.5M | $167.6M | $98.7M | $90.9M |
Frequently Asked Questions
How does Cytek Biosciences, Inc. make money?
The company's revenue primarily stems from the sale of high-end flow cytometers and imaging systems, along with proprietary optical components and software solutions. Revenue streams also include the licensing of intellectual property related to spectral cytometry technology and after-market support services such as calibration kits and data analysis tools.
What are the main risks for CTKB?
Significant financial distress is evident with a massive net loss of $66.5M in 2025 and a negative operating cash flow of $4.7M, raising concerns about sustainability without external funding. The company carries a substantial retained earnings deficit of over $100M which limits flexibility for aggressive R&D expansion or share buybacks. High capital expenditures relative to revenue suggest heavy asset investment that may not yet be yielding proportional returns given the current loss trajectory. Dependence on a narrow set of high-end scientific instruments makes the business vulnerable to cyclical declines in research funding.
What is CTKB's competitive advantage?
CTKB holds a dominant position in single-cell analysis due to its unique spectral cytometry technology which eliminates the need for fluorochrome compensation. The company possesses strong intellectual property barriers protecting its optical design and proprietary algorithms that differentiate it from competitors like BD Biosciences and Beckman Coulter. Its direct-to-laboratory sales model allows for rapid deployment of cutting-edge instruments directly into research institutions.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.